Deep vein thrombosis and pulmonary embolism

The Lancet

Volumn 388, Issue 10063, 2016, Pages 3060-3073

  Di Nisio, Marcello ^a,b   van Es, Nick ^b   Büller, Harry R ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRINOLYTIC AGENT; FIBRIN DEGRADATION PRODUCT;

ANTICOAGULANT THERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPRESSION STOCKING; DIAGNOSTIC IMAGING; FIBRINOLYTIC THERAPY; HOME CARE; HUMAN; INCIDENCE; LEG THROMBOSIS; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; VENA CAVA FILTER; BLEEDING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; PULMONARY EMBOLISM; RISK FACTOR; VENOUS THROMBOSIS;

ANTICOAGULANTS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMORRHAGE; PULMONARY EMBOLISM; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; ULTRASONOGRAPHY; VENOUS THROMBOSIS;

EID: 85003443860     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30514-1     Document Type: Review

References (156)

1. 1 Raskob, GE, Angchaisuksiri, P, Blanco, AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 34 (2014), 2363–2371.
2. 2 Cohen, AT, Agnelli, G, Anderson, FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98 (2007), 756–764.
3. 3 Grosse, SD, Nelson, RE, Nyarko, KA, Richardson, LC, Raskob, GE, The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 137 (2016), 3–10.
4. 4 Huang, W, Goldberg, RJ, Anderson, FA, Kiefe, CI, Spencer, FA, Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009). Am J Med, 127, 2014, 829 39.e5.
5. 5 Jensvoll, H, Severinsen, MT, Hammerstrøm, J, et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol 7 (2015), 401–410.
6. 6 Heit, JA, Epidemiology of venous thromboembolism. Nat Rev Cardiol 12 (2015), 464–474.
7. 7 Bell, EJ, Lutsey, PL, Basu, S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 129 (2016), 339.e19–339.e26.
8. 8 Deitelzweig, SB, Lin, J, Johnson, BH, Schulman, KL, Venous thromboembolism in the US: does race matter?. J Thromb Thrombolysis 31 (2011), 133–138.
9. 9 Roach, REJ, Lijfering, WM, Rosendaal, FR, Cannegieter, SC, Le Cessie, S, Sex difference in risk of second but not of first venous thrombosis: paradox explained. Circulation 129 (2014), 51–56.
10. 10 Sogaard, KK, Schmidt, M, Pedersen, L, Horvath-Puho, E, Sorensen, HT, 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 130 (2014), 829–936.
11. 11 Stein, PD, Matta, F, Alrifai, A, Rahman, A, Trends in case fatality rate in pulmonary embolism according to stability and treatment. Thromb Res 130 (2012), 1–6.
12. 12 Goldhaber, SZ, Visani, L, De Rosa, M, Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353 (1999), 1386–1389.
13. 13 Kearon, C, Natural history of venous thromboembolism. Circulation 107 (2003), I22–I30.
14. 14 Kahn, SR, Comerota, AJ, Cushman, M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies. Circulation 130 (2014), 1636–1661.
15. 15 Hoeper, MM, Madani, MM, Nakanishi, N, Meyer, B, Cebotari, S, Rubin, LJ, Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2 (2014), 573–582.
16. 16 Kearon, C, Ageno, W, Cannegieters, SC, Cosmi, B, Geersing, G-J, Kyrle, PA, for The subcommittees on Control of Anticoagulation and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked VTE: guidance from the SSC of ISTH. J Thromb Haemost 14 (2016), 1–4.
17. 17 Rosendaal, FR, Venous thrombosis: a multicausal disease. Lancet 353 (1999), 1167–1173.
18. 18 Januel, J-M, Chen, G, Ruffieux, C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 307 (2012), 294–303.
19. 19 Timp, JF, Braekkan, SK, Versteeg, HH, Cannegieter, SC, Epidemiology of cancer-associated venous thrombosis. Blood 122 (2013), 1712–1723.
20. 20 MacCallum, P, Bowles, L, Keeling, D, Diagnosis and management of heritable thrombophilias. BMJ, 349, 2014, g4387 g4387.
21. 21 Morange, P-E, Suchon, P, Trégouët, D-A, Genetics of venous thrombosis: update in 2015. Thromb Haemost 114 (2015), 910–919.
22. 22 Stein, PD, Matta, F, Musani, MH, Diaczok, B, Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med 123 (2010), 426–431.
23. 23 Pollack, C V, Schreiber, D, Goldhaber, SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 57 (2011), 700–706.
24. 24 Ceriani, E, Combescure, C, Le Gal, G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost 8 (2010), 957–970.
25. 25 Lucassen, W, Geersing, GJ, Erkens, PMG, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med 155 (2011), 448–460.
26. 26 Geersing, GJ, Zuithoff, NPA, Kearon, C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 348, 2014, g1340.
27. 27 Wells, PS, Anderson, DR, Rodger, M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349 (2003), 1227–1235.
28. 28 Wells, PS, Anderson, DR, Rodger, M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83 (2000), 416–420.
29. 29 Gibson, NS, Sohne, M, Kruip, MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost 99 (2008), 229–234.
30. 30 Le Gal, G, Righini, M, Roy, P-M, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 144 (2006), 165–171.
31. 31 Klok, FA, Mos, ICM, Nijkeuter, M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med 168 (2008), 2131–2136.
32. 32 Wells, PS, Anderson, DR, Bormanis, J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350 (1997), 1795–1798.
33. 33 Righini, M, Van Es, J, Den Exter, PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 311 (2014), 1117–1124.
34. 34 Douma, RA, Mos, ICM, Erkens, PMG, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med 154 (2011), 709–718.
35. 35 van Belle, A, Büller, HR, Huisman, M V, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 295 (2006), 172–179.
36. 36 Di Nisio, M, Squizzato, A, Rutjes, AWS, Büller, HR, Zwinderman, AH, Bossuyt, PMM, Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 5 (2007), 296–304.
37. 37 Geersing, GJ, Janssen, KJM, Oudega, R, et al. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. BMJ, 339, 2009, b2990.
38. 38 Büller, HR, Ten Cate-Hoek, AJ, Hoes, AW, et al. Safely ruling out deep venous thrombosis in primary care. Ann Intern Med 150 (2009), 229–235.
39. 39 Wells, PS, Anderson, DR, Rodger, M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 135 (2001), 98–107.
40. 40 Silveira, PC, Ip, IK, Goldhaber, SZ, Piazza, G, Benson, CB, Khorasani, R, Performance of Wells score for deep vein thrombosis in the inpatient setting. JAMA Intern Med 175 (2015), 1112–1117.
41. 41 Douma, RA, van Sluis, GL, Kamphuisen, PW, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 104 (2010), 831–836.
42. 42 Raja, AS, Greenberg, JO, Qaseem, A, et al. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 163 (2015), 701–711.
43. 43 Mos, ICM, Douma, RA, Erkens, PMG, et al. Diagnostic outcome management study in patients with clinically suspected recurrent acute pulmonary embolism with a structured algorithm. Thromb Res 133 (2014), 1039–1044.
44. 44 van Es, N, van der Hulle, T, van Es, J, et al. Wells rule and D-dimer testing to rule out pulmonary embolism: a systematic review and individual-patient data meta-analysis. Ann Intern Med, 2016, 10.7326/M16-0031 published online May 17.
45. 45 Chan, W, Lee, AY, Spencer, FA, et al. Predicting deep venous thrombosis in pregnancy: out in ‘LEFt’ field?. Ann Intern Med 151 (2009), 85–92.
46. 46 Douma, RA, le Gal, G, Söhne, M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ, 340, 2010, c1475.
47. 47 Schouten, HJ, Geersing, GJ, Koek, HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ, 346, 2013, f2492.
48. 48 Penaloza, A, Roy, PM, Kline, J, et al. Performance of age-adjusted D-dimer cut-off to rule out pulmonary embolism. J Thromb Haemost 10 (2012), 1291–1296.
49. 49 Singh, B, Mommer, SK, Erwin, PJ, Mascarenhas, SS, Parsaik, AK, Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism—revisited: a systematic review and meta-analysis. Emerg Med J 30 (2013), 701–706.
50. 50 Hugli, O, Righini, M, Le Gal, G, et al. The pulmonary embolism rule-out criteria (PERC) rule does not safely exclude pulmonary embolism. J Thromb Haemost 9 (2011), 300–304.
51. 51 Perrier, A, Nendaz, MR, Sarasin, FP, Howarth, N, Bounameaux, H, Cost-effectiveness analysis of diagnostic strategies for suspected pulmonary embolism including helical computed tomography. Am J Respir Crit Care Med 167 (2003), 39–44.
52. 52 Roy, P-M, Meyer, G, Vielle, B, et al. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med 144 (2006), 157–164.
53. 53 Runyon, MS, Richman, PB, Kline, JA, Emergency medicine practitioner knowledge and use of decision rules for the evaluation of patients with suspected pulmonary embolism: variations by practice setting and training level. Acad Emerg Med 14 (2007), 53–57.
54. 54 Bates, SM, Jaeschke, R, Stevens, SM, et al. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e351S–e418S.
55. 55 Johnson, SA, Stevens, SM, Woller, SC, et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 303 (2010), 438–445.
56. 56 Bernardi, E, Camporese, G, Büller, HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 300 (2008), 1653–1659.
57. 57 Righini, M, Paris, S, Le Gal, G, Laroche, J-P, Perrier, A, Bounameaux, H, Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemost 95 (2006), 56–64.
58. 58 Cogo, A, Lensing, AW, Koopman, MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 316 (1998), 17–20.
59. 59 Elias, A, Mallard, L, Elias, M, et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. Thromb Haemost 89 (2003), 221–227.
60. 60 Birdwell, BG, Raskob, GE, Whitsett, TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 128 (1998), 1–7.
61. 61 Schellong, SM, Schwarz, T, Halbritter, K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 89 (2003), 228–234.
62. 62 Schwarz, T, Schmidt, B, Schmidt, B, Schellong, SM, Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. Clin Appl Thromb 8 (2002), 45–49.
63. 63 Camporese, G, Bernardi, E, Scarano, L, et al. Outcome of patients with suspected lower limb symptomatic deep vein thrombosis and a normal ultrasound-based initial diagnostic workup: a prospective study. J Thromb Haemost 10 (2012), 2605–2606.
64. 64 Palareti, G, How I treat isolated distal deep vein thrombosis (IDDVT). Blood 123 (2014), 1802–1809.
65. 65 Kearon, C, Ginsberg, JS, Hirsh, J, The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 129 (1998), 1044–1049.
66. 66 Wells, PS, Owen, C, Doucette, S, Fergusson, D, Tran, H, Does this patient have deep vein thrombosis?. JAMA 295 (2006), 199–207.
67. 67 Kraaijenhagen, RA, Piovella, F, Bernardi, E, et al. Simplification of the diagnostic management of suspected deep vein thrombosis. Arch Intern Med 162 (2002), 907–911.
68. 68 Ageno, W, Camporese, G, Riva, N, et al., for the PALLADIO study investigators. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol 2 (2015), e474–e480.
69. 69 Liu, D, Peterson, E, Dooner, J, et al. Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline. CMAJ 187 (2015), 1288–1296.
70. 70 Linkins, L-A, Stretton, R, Probyn, L, Kearon, C, Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. Thromb Res 117 (2006), 241–247.
71. 71 Tan, M, Mol, GC, van Rooden, CJ, et al. Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. Blood 124 (2014), 623–627.
72. 72 Van Beek, EJR, Brouwers, EMJ, Song, BIN, Stein, PD, Oudkerk, M, Clinical validity of a normal pulmonary angiogram in patients with suspected pulmonary embolism—a critical review. Clin Radiol 56 (2001), 838–842.
73. 73 Moores, LK, Jackson, WL, Shorr, AF, Jackson, JL, Meta-analysis: outcomes in patients with suspected pulmonary embolism managed with computed tomographic pulmonary angiography. Ann Intern Med 141 (2004), 866–874.
74. 74 PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 263 (1990), 2753–2759.
75. 75 Huisman, M.V., Klok, FA, Diagnostic management of clinically suspected acute pulmonary embolism. J Thromb Haemost 7 (2009), 312–317.
76. 76 Carrier, M, Righini, M, Le Gal, G, Symptomatic subsegmental pulmonary embolism: what is the next step?. J Thromb Haemost 10 (2012), 1486–1490.
77. 77 Righini, M, Le Gal, G, Aujesky, D, et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet 371 (2008), 1343–1352.
78. 78 Anderson, DR, Kahn, SR, Rodger, MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 298 (2007), 2743–2753.
79. 79 Konstantinides, S V, Torbicki, A, Agnelli, G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 (2014), 3033–3069.
80. 80 Ageno, W, Squizzato, A, Wells, PS, Büller, HR, Johnson, G, The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 11 (2013), 1597–1602.
81. 81 den Exter, PL, van Es, J, Kroft, LJM, et al. Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. Thromb Haemost 114 (2015), 1–9.
82. 82 Stein, PD, Chenevert, TL, Fowler, SE, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism. Ann Intern Med 152 (2010), 434–443.
83. 83 Stein, PD, Freeman, LM, Sostman, HD, et al. SPECT in acute pulmonary embolism. J Nucl Med 50 (2009), 1999–2007.
84. 84 Huisman, M V, Klok, FA, Magnetic resonance imaging for diagnosis of acute pulmonary embolism: not yet a suitable alternative to CT-PA. J Thromb Haemost 10 (2012), 741–742.
85. 85 Wells, PS, Forgie, MA, Rodger, MA, Treatment of venous thromboembolism. JAMA 311 (2014), 717–728.
86. 86 Erkens, PM, Prins, MH, Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev, 9, 2010 CD001100.
87. 87 Castellucci, LA, Cameron, C, Le Gal, G, et al. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 312 (2014), 1122–1135.
88. 88 Linkins, L-A, Treatment and prevention of heparin-induced thrombocytopenia. Chest, 141, 2012, e495S.
89. 89 Heidbuchel, H, Verhamme, P, Alings, M, et al. Updated European Heart Rhythm Association practical guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
90. 90 Agnelli, G, Buller, HR, Cohen, A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
91. 91 Büller, HR, Prins, MH, Lensin, AWA, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
92. 92 Bauersachs, R, Berkowitz, SD, Brenner, B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
93. 93 Hokusai-VTE Investigators, Büller, HR, Décousus, H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
94. 94 Schulman, S, Kearon, C, Kakkar, AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
95. 95 Schulman, S, Kakkar, AK, Goldhaber, SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
96. 96 van Es, N, Coppens, M, Schulman, S, Middeldorp, S, Büller, HR, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124 (2014), 1968–1975.
97. 97 Kearon, C, Akl, EA, Ornelas, J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 149 (2016), 315–352.
98. 98 Beyer-Westendorf, J, Ageno, W, Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 113 (2014), 1–16.
99. 99 Ageno, W, Mantovani, LG, Haas, S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol 3 (2016), e12–e21.
100. 100 Pollack, C V, Reilly, PA, Eikelboom, J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 373 (2015), 511–520.
101. 101 Ansell, JE, Bakhru, SH, Laulicht, BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371 (2014), 2141–2142.
102. 102 Siegal, DM, Curnutte, JT, Connolly, SJ, et al. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 373 (2015), 2413–2424.
103. 103 Eerenberg, ES, Middeldorp, S, Levi, M, Lensing, AW, Büller, HR, Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 13 (2015), 1590–1596.
104. 104 Beyer-Westendorf, J, Förster, K, Pannach, S, et al. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. Blood 124 (2014), 955–963.
105. 105 Caldeira, D, Rodrigues, FB, Barra, M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 101 (2015), 1204–1211.
106. 106 Lee, AY, Levine, MN, Baker, RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003), 146–153.
107. 107 Lee, AYY, Kamphuisen, PW, Meyer, G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314 (2015), 677–686.
108. 108 Akl, EA, Kahale, L, Barba, M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev, 7, 2014 CD006650.
109. 109 Zondag, W, Mos, ICM, Creemers-Schild, D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 9 (2011), 1500–1507.
110. 110 Aujesky, D, Obrosky, DS, Stone, RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172 (2005), 1041–1046.
111. 111 Jiménez, D, Aujesky, D, Moores, L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170 (2010), 1383–1389.
112. 112 Squizzato, A, Donadini, MP, Galli, L, Dentali, F, Aujesky, D, Ageno, W, Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost 10 (2012), 1276–1290.
113. 113 Aujesky, D, Roy, P-M, Verschuren, F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 378 (2011), 41–48.
114. 114 Meyer, G, Vicaut, E, Danays, T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370 (2014), 1402–1411.
115. 115 Enden, T, Haig, Y, Kløw, N-E, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 379 (2012), 31–38.
116. 116 Haig, Y, Enden, T, Grøtta, O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol 3 (2016), e64–e71.
117. 117 Bashir, R, Zack, CJ, Zhao, H, Comerota, AJ, Bove, AA, Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med 174 (2014), 1494–1501.
118. 118 Mismetti, P, Laporte, S, Pellerin, O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA 313 (2015), 1627–1635.
119. 119 Sarosiek, S, Crowther, M, Sloan, JM, Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 173 (2013), 513–517.
120. 120 Stein, PD, Matta, F, Hull, RD, Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 124 (2011), 655–661.
121. 121 Spencer, FA, Bates, SM, Goldberg, RJ, et al. A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med 170 (2010), 1456–1462.
122. 122 Brandjes, DP, Büller, HR, Heijboer, H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997), 759–762.
123. 123 Prandoni, P, Lensing, AWA, Prins, MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004), 249–256.
124. 124 Kahn, SR, Shapiro, S, Wells, PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 6736 (2013), 1–9.
125. 125 Ost, D, Tepper, J, Mihara, H, Lander, O, Heinzer, R, Fein, A, Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 294 (2005), 706–715.
126. 126 Kearon, C, Gent, M, Hirsh, J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999), 901–907.
127. 127 Linkins, L-A, Choi, PT, Douketis, JD, Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139 (2003), 893–900.
128. 128 Carrier, M, Le Gal, G, Wells, PS, Rodger, MA, Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 152 (2010), 578–589.
129. 129 Baglin, T, Bauer, K, Douketis, J, et al. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost 10 (2012), 698–702.
130. 130 Rodger, M, Carrier, M, Gandara, E, Le Gal, G, Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev 24 (2010), 171–178.
131. 131 Kearon, C, Iorio, A, Palareti, G, for the Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 8 (2010), 2313–2315.
132. 132 Baglin, T, Douketis, J, Tosetto, A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 8 (2010), 2436–2442.
133. 133 Couturaud, F, Sanchez, O, Pernod, G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 314 (2015), 31–40.
134. 134 Iorio, A, Kearon, C, Filippucci, E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170 (2010), 1710–1716.
135. 135 Boutitie, F, Pinede, L, Schulman, S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ, 342, 2011, d3036.
136. 136 Rodger, MA, Kahn, SR, Wells, PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179 (2008), 417–426.
137. 137 Tosetto, A, Iorio, A, Marcucci, M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (DASH). J Thromb Haemost 10 (2012), 1019–1025.
138. 138 Eichinger, S, Heinze, G, Jandeck, LM, Kyrle, PA, Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 121 (2010), 1630–1636.
139. 139 Kearon, C, Spencer, FA, O'Keeffe, D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 162 (2015), 27–34.
140. 140 Palareti, G, Cosmi, B, Legnani, C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood 124 (2014), 196–203.
141. 141 Palareti, G, Cosmi, B, Legnani, C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355 (2006), 1780–1789.
142. 142 Cosmi, B, Legnani, C, Tosetto, A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115 (2010), 481–488.
143. 143 Carrier, M, Rodger, MA, Wells, PS, Righini, M, Le Gal, G, Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 9 (2011), 1119–1125.
144. 144 Verhovsek, M, Douketis, JD, Yi, Q, Shrivastava, S, Tait, RC, Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149 (2008), 481–490.
145. 145 Riva, N, Bellesini, M, Di Minno, MND, et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. Thromb Haemost 112 (2014), 511–521.
146. 146 Di Nisio, M, Ageno, W, Rutjes, AWS, Pap, AF, Büller, HR, Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thromb Haemost 115 (2016), 424–432.
147. 147 Carrier, M, Khorana, AA, Zwicker, JI, Noble, S, Lee, AYY, Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. J Thromb Haemost 12 (2014), 115–116.
148. 148 Castellucci, LA, Cameron, C, Le Gal, G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ, 347, 2013, f5133.
149. 149 Schulman, S, Kearon, C, Kakkar, AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368 (2013), 709–718.
150. 150 Raskob, G, Ageno, W, Cohen, AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 3 (2016), e228–e236.
151. 151 Agnelli, G, Buller, HR, Cohen, A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
152. 152 Brighton, TA, Eikelboom, JW, Mann, K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367 (2012), 1979–1987.
153. 153 Becattini, C, Agnelli, G, Schenone, A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366 (2012), 1959–1967.
154. 154 Simes, J, Becattini, C, Agnelli, G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 130 (2014), 1062–1071.
155. 155 Andreozzi, GM, Bignamini, AA, Davì, G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 132 (2015), 1891–1897.
156. 156 Schmidt, M, Cannegieter, SC, Johannesdottir, SA, Dekkers, OM, Horváth-Puhó, E, Sørensen, HT, Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost 12 (2014), 1207–1215.